BIOMAT Database Logo BIOMAT Database Logo

Antihypertensive beta-adrenergic blocking agents: N-aralkyl analogues of 2-[3-(tert-butylamino)-2-hydroxypropoxy]-3-cyanopyridine. 1983

D E McClure, and J J Baldwin, and W C Randall, and T F Lyon, and K Mensler, and G F Lundell, and A W Raab, and D Gross, and E A Risley, and C S Sweet, and M Williams

An interest in dual-acting antihypertensive agents, specifically those related to (S)-2-[3-(tert-butylamino)-2-hydroxypropoxy]-3-cyanopyridine (1), led us to probe the contribution of the side-chain amino substituent in this series. The ability of 1 and its various analogues to displace radiolabeled alpha 1 (WB-4101 and prazosin) and beta (dihydroalprenolol) adrenergic receptor ligands was assessed by receptor-binding techniques. Most of the compounds exhibited high beta-adrenoceptor binding affinities, but only the N-aralkylamino-substituted compounds showed high alpha 1-adrenoceptor affinities. Therefore, the vasodilation shown by 1 was not due to an interaction with the alpha 1 adrenoceptor. The aralkylamino analogues of 1 in spontaneously hypertensive rats and anesthetized dogs exhibited antihypertensive activity and alpha 1-adrenoceptor blocking properties. Unlike the preference shown by beta-adrenoceptors for S enantiomers in this oxymethylene class of beta blockers, the chirality at the secondary hydroxy center made only a minor contribution to the affinity for the alpha 1-adrenoceptor and even less of a contribution to the observed antihypertensive effects. This lack of chiral influence at the hydroxy center confirmed what had been previously observed in more limited studies with the isomers of both labetalol and medroxalol.

UI MeSH Term Description Entries
D011224 Prazosin A selective adrenergic alpha-1 antagonist used in the treatment of HEART FAILURE; HYPERTENSION; PHEOCHROMOCYTOMA; RAYNAUD DISEASE; PROSTATIC HYPERTROPHY; and URINARY RETENTION. Furazosin,Minipress,Pratsiol,Prazosin HCL,Prazosin Hydrochloride,HCL, Prazosin,Hydrochloride, Prazosin
D011725 Pyridines Compounds with a six membered aromatic ring containing NITROGEN. The saturated version is PIPERIDINES.
D011943 Receptors, Adrenergic, beta One of two major pharmacologically defined classes of adrenergic receptors. The beta adrenergic receptors play an important role in regulating CARDIAC MUSCLE contraction, SMOOTH MUSCLE relaxation, and GLYCOGENOLYSIS. Adrenergic beta-Receptor,Adrenergic beta-Receptors,Receptors, beta-Adrenergic,beta Adrenergic Receptor,beta-Adrenergic Receptor,beta-Adrenergic Receptors,Receptor, Adrenergic, beta,Adrenergic Receptor, beta,Adrenergic beta Receptor,Adrenergic beta Receptors,Receptor, beta Adrenergic,Receptor, beta-Adrenergic,Receptors, beta Adrenergic,beta Adrenergic Receptors,beta-Receptor, Adrenergic,beta-Receptors, Adrenergic
D002540 Cerebral Cortex The thin layer of GRAY MATTER on the surface of the CEREBRAL HEMISPHERES that develops from the TELENCEPHALON and folds into gyri and sulci. It reaches its highest development in humans and is responsible for intellectual faculties and higher mental functions. Allocortex,Archipallium,Cortex Cerebri,Cortical Plate,Paleocortex,Periallocortex,Allocortices,Archipalliums,Cerebral Cortices,Cortex Cerebrus,Cortex, Cerebral,Cortical Plates,Paleocortices,Periallocortices,Plate, Cortical
D004082 Dihydroalprenolol Hydrogenated alprenolol derivative where the extra hydrogens are often tritiated. This radiolabeled form of ALPRENOLOL, a beta-adrenergic blocker, is used to label the beta-adrenergic receptor for isolation and study. 1-((Methylethyl)amino)-3-(2-propylphenoxy)-2-propanol
D004146 Dioxanes Compounds that contain the structure 1,4-dioxane.
D000319 Adrenergic beta-Antagonists Drugs that bind to but do not activate beta-adrenergic receptors thereby blocking the actions of beta-adrenergic agonists. Adrenergic beta-antagonists are used for treatment of hypertension, cardiac arrhythmias, angina pectoris, glaucoma, migraine headaches, and anxiety. Adrenergic beta-Antagonist,Adrenergic beta-Receptor Blockader,Adrenergic beta-Receptor Blockaders,beta-Adrenergic Antagonist,beta-Adrenergic Blocker,beta-Adrenergic Blocking Agent,beta-Adrenergic Blocking Agents,beta-Adrenergic Receptor Blockader,beta-Adrenergic Receptor Blockaders,beta-Adrenoceptor Antagonist,beta-Blockers, Adrenergic,beta-Adrenergic Antagonists,beta-Adrenergic Blockers,beta-Adrenoceptor Antagonists,Adrenergic beta Antagonist,Adrenergic beta Antagonists,Adrenergic beta Receptor Blockader,Adrenergic beta Receptor Blockaders,Adrenergic beta-Blockers,Agent, beta-Adrenergic Blocking,Agents, beta-Adrenergic Blocking,Antagonist, beta-Adrenergic,Antagonist, beta-Adrenoceptor,Antagonists, beta-Adrenergic,Antagonists, beta-Adrenoceptor,Blockader, Adrenergic beta-Receptor,Blockader, beta-Adrenergic Receptor,Blockaders, Adrenergic beta-Receptor,Blockaders, beta-Adrenergic Receptor,Blocker, beta-Adrenergic,Blockers, beta-Adrenergic,Blocking Agent, beta-Adrenergic,Blocking Agents, beta-Adrenergic,Receptor Blockader, beta-Adrenergic,Receptor Blockaders, beta-Adrenergic,beta Adrenergic Antagonist,beta Adrenergic Antagonists,beta Adrenergic Blocker,beta Adrenergic Blockers,beta Adrenergic Blocking Agent,beta Adrenergic Blocking Agents,beta Adrenergic Receptor Blockader,beta Adrenergic Receptor Blockaders,beta Adrenoceptor Antagonist,beta Adrenoceptor Antagonists,beta Blockers, Adrenergic,beta-Antagonist, Adrenergic,beta-Antagonists, Adrenergic,beta-Receptor Blockader, Adrenergic,beta-Receptor Blockaders, Adrenergic
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D000959 Antihypertensive Agents Drugs used in the treatment of acute or chronic vascular HYPERTENSION regardless of pharmacological mechanism. Among the antihypertensive agents are DIURETICS; (especially DIURETICS, THIAZIDE); ADRENERGIC BETA-ANTAGONISTS; ADRENERGIC ALPHA-ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CALCIUM CHANNEL BLOCKERS; GANGLIONIC BLOCKERS; and VASODILATOR AGENTS. Anti-Hypertensive,Anti-Hypertensive Agent,Anti-Hypertensive Drug,Antihypertensive,Antihypertensive Agent,Antihypertensive Drug,Anti-Hypertensive Agents,Anti-Hypertensive Drugs,Anti-Hypertensives,Antihypertensive Drugs,Antihypertensives,Agent, Anti-Hypertensive,Agent, Antihypertensive,Agents, Anti-Hypertensive,Agents, Antihypertensive,Anti Hypertensive,Anti Hypertensive Agent,Anti Hypertensive Agents,Anti Hypertensive Drug,Anti Hypertensive Drugs,Anti Hypertensives,Drug, Anti-Hypertensive,Drug, Antihypertensive,Drugs, Anti-Hypertensive,Drugs, Antihypertensive
D001667 Binding, Competitive The interaction of two or more substrates or ligands with the same binding site. The displacement of one by the other is used in quantitative and selective affinity measurements. Competitive Binding

Related Publications

D E McClure, and J J Baldwin, and W C Randall, and T F Lyon, and K Mensler, and G F Lundell, and A W Raab, and D Gross, and E A Risley, and C S Sweet, and M Williams
Heterocyclic analogues of the antihypertensive beta-adrenergic blocking agent (S)-2-[3-(ter-butylamino)-2-hydroxypropoxy]-3-cyanopyridine.
January 1980, Journal of medicinal chemistry,
D E McClure, and J J Baldwin, and W C Randall, and T F Lyon, and K Mensler, and G F Lundell, and A W Raab, and D Gross, and E A Risley, and C S Sweet, and M Williams
Antihypertensive and hemodynamic properties of 2-(3-tert-butylamino-2-hydroxypropoxy)-3-cyanopyridine HCl (MK-761).
October 1979, The Journal of pharmacology and experimental therapeutics,
D E McClure, and J J Baldwin, and W C Randall, and T F Lyon, and K Mensler, and G F Lundell, and A W Raab, and D Gross, and E A Risley, and C S Sweet, and M Williams
GLC determination of S-2-(3-tert-butylamino-2-hydroxypropoxy)-3-cyanopyridine in human plasma.
December 1979, Journal of pharmaceutical sciences,
D E McClure, and J J Baldwin, and W C Randall, and T F Lyon, and K Mensler, and G F Lundell, and A W Raab, and D Gross, and E A Risley, and C S Sweet, and M Williams
[Synthesis of 5-(3-tert-butylamino-2-hydroxypropoxy)-8-hydroxy-3,4-dihydrocarbostyril hydrochloride and its beta-adrenergic blocking activity].
May 1976, Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan,
D E McClure, and J J Baldwin, and W C Randall, and T F Lyon, and K Mensler, and G F Lundell, and A W Raab, and D Gross, and E A Risley, and C S Sweet, and M Williams
BETA-Adrenergic blocking agents. 13. (3-Amino-2-hydroxypropoxy)benzamides.
September 1976, Journal of medicinal chemistry,
D E McClure, and J J Baldwin, and W C Randall, and T F Lyon, and K Mensler, and G F Lundell, and A W Raab, and D Gross, and E A Risley, and C S Sweet, and M Williams
Beta-adrenergic blocking agents. 10. (3-amino-2-hydroxypropoxy)anilides.
June 1971, Journal of medicinal chemistry,
D E McClure, and J J Baldwin, and W C Randall, and T F Lyon, and K Mensler, and G F Lundell, and A W Raab, and D Gross, and E A Risley, and C S Sweet, and M Williams
The metabolic disposition of (S)-2-(3-tert-butylamino-2-hydroxypropoxy)-3-cyanopyridine in rats, dogs, and humans.
January 1980, Drug metabolism and disposition: the biological fate of chemicals,
D E McClure, and J J Baldwin, and W C Randall, and T F Lyon, and K Mensler, and G F Lundell, and A W Raab, and D Gross, and E A Risley, and C S Sweet, and M Williams
[Synthesis of optically active 5- (3-tert-butylamino-2-hydroxypropoxy)-3,4-dihydrocarbostyril hydrochloride and their beta-adrenergic blocking activities (author's transl)].
March 1976, Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan,
D E McClure, and J J Baldwin, and W C Randall, and T F Lyon, and K Mensler, and G F Lundell, and A W Raab, and D Gross, and E A Risley, and C S Sweet, and M Williams
Chronic effects of a beta-adrenoceptor blocking drug, 4-[3-(tert-butylamino)-2-hydroxypropoxy]-N-methylisocarbostyril hydrochloride (N-696), in hypertensive rats.
February 1985, Journal of pharmacobio-dynamics,
D E McClure, and J J Baldwin, and W C Randall, and T F Lyon, and K Mensler, and G F Lundell, and A W Raab, and D Gross, and E A Risley, and C S Sweet, and M Williams
Pharmacological profile of a new beta-adrenoceptor blocker, 4-[3-(tert-butylamino)-2-hydroxypropoxy]-N-methylisocarbostyril hydrochloride (N-696).
January 1984, Arzneimittel-Forschung,
Copied contents to your clipboard!